Navigation Links
Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic

CAMBRIDGE, Mass., April 11, 2007 /PRNewswire-FirstCall/ -- Advanced Magnetics today announced positive results from two additional Phase III clinical trials of ferumoxytol as an intravenous (IV) iron replacement therapeutic that are being presented today at approximately 6:00 pm EDT as posters at the National Kidney Foundation's Spring Clinical Meeting in Orlando, Florida. These posters are available in the investor section on the company's web site at http://www.advancedmagnetics.com.

The first poster, "Evaluation of the Efficacy and Safety of Ferumoxytol as an Intravenous Iron Replacement Therapy in Chronic Kidney Disease (CKD) Patients Not on Dialysis" shows results from 303 non-dialysis dependent CKD patients who were randomized to receive either two 510 mg doses of ferumoxytol within one week or 200 mg of oral iron daily for three weeks. This Phase III study demonstrated a statistically significant achievement of all primary and secondary endpoints. Additionally, all primary and secondary endpoints were achieved with statistical significance in both patients on erythropoiesis stimulating proteins (ESP) and those not on ESPs. These new results are consistent with the results previously presented at the American Society of Nephrology's Renal Week in San Diego, CA in November 2006 from another study in non-dialysis dependent CKD patients with an identical protocol.

The second poster, "Evaluation of the Safety of Intravenous Ferumoxytol for Iron Replacement Therapy in Chronic Kidney Disease (CKD)" shows results from a double-blind, placebo-controlled, crossover Phase III study which enrolled a total of 750 patients, including both dialysis-dependent CKD patients and non-dialysis dependent CKD patients, who received either one 510 mg dose of ferumoxytol or IV placebo (saline) at day zero and received the other treatment at day seven.
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
10. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... gefragt. Das Problem dabei ist, dass ... mit der Kompetenz zu teilen. Es ... deshalb freuen wir uns umso mehr, dass es ... ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit einem ...
(Date:10/17/2014)... 2014 With the recent changes in ... come across several challenges in creating and utilizing ... The Medical Affairs Consortium ... providing benchmarking and best practices across critical Medical ... service composed of three stages: 1) member-driven topic ...
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Antibacterial Products aimed at reducing cross contamination ... infections ... Corporation,announced today the SILVER SEAL(TM) family of antibacterial products for,infection ... and Mouse. According to the company, the,SILVER SEAL(TM) Keyboard and ...
... - Once Granted by the European Commission, ATRIPLA Would Represent the, First ... ... Union -, PRINCETON, N.J., FOSTER CITY, Calif. and WHITEHOUSE STATION, N.J., ... GILD ) and Merck & Co., Inc. (NYSE: MRK ),announced ...
Cached Medicine Technology:Seal Shield Launches World's First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control 2Seal Shield Launches World's First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control 3European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 2European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 3European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 4European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 5European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 6European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 7European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 8European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 9European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 10
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Hastings and ... 30 years of service throughout the greater Phoenix area ... legal representation with regard to catastrophic automobile accidents. Statistics ... the country and throughout Arizona. As such, Hastings and ... for legal representation for those who have been injured ...
(Date:10/19/2014)... This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ... late-stage and discontinued projects. , Partial Seizures are ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
(Date:10/19/2014)... that causes inflammation in the spinal joints and ... ancient Egyptian royal families. Now a new study ... journal of the American College of Rheumatology (ACR), ... condition called diffuse idiopathic skeletal hyperostosis (DISH) in ... 20th Dynasties. , Ankylosing spondylitis is a ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... 2008) Two Mayo Clinic researchers who study the role ... the formation of kidney stones, will lead a symposium on ... symposium will take place April 8 at the Experimental Biology ... smaller than the bacteria, E. coli, but recent advances in ...
... Group And Digital Peach Interactive Group Unite To ... Networks To Improve Women,s Healthcare, NEW YORK, ... company,comprised of multiple specialized and related businesses focused ... today a,unique partnership that will engage, connect and ...
... Leading Maker of Rugged Computers Donates GoBook(R) XR-1 Notebooks to ... Support ... General Dynamics,Itronix, an industry leading maker of rugged notebook ... Expedition,2008: Fighting Malaria on the "River of Life." The XR-1 ...
... from overweight, high blood pressure and metabolic disturbances ... is the result of a study with almost ... of the Deutsches rzteblatt International (Dtsch Arztebl Int ... The so-called metabolic syndrome describes a typical constellation ...
... finds having autistic child shrinks family income by 14% , , ... additional light on two different aspects of autism: One tried ... while the other looked at the financial toll that having ... were expected to be published in the April issue of ...
... 2008 MedCath,Corporation (Nasdaq: MDTH ) announced ... percent interest in a joint venture known as ... venture provides cardiac,catheterization lab services to Yuma Regional ... Management and Service Agreement with,the Hospital., The ...
Cached Medicine News:Health News:Symposium to explore role nanoparticles may play in disease 2Health News:Kinetix Creates Innovative Online Model to Engage and Educate Healthcare Professionals 2Health News:General Dynamics Itronix Donates Computers to Humanitarian Expedition Fighting Malaria in Africa 2Health News:General Dynamics Itronix Donates Computers to Humanitarian Expedition Fighting Malaria in Africa 3Health News:Very Premature Babies Show Raised Risk for Autism 2Health News:Very Premature Babies Show Raised Risk for Autism 3Health News:MedCath Announces Acquisition of Ownership in Arizona Cath Lab 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: